Therapeutic | Eldelumab |
Target | CXCL10 |
Heavy Chain | QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS |
Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | Medarex UltiMAb Mouse |
INN Year Proposed | 2013 |
INN Year Recommended | 2014 |
Companies Involved | Bristol-Myers Squibb, Medarex |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Crohn's disease, Ulcerative colitis, Multiple sclerosis, Rheumatoid arthritis, Spinal cord injuries |
Notes |